

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 6 February 2021

Situation Report No. 228 - Kingdom of Bahrain

7th of February, 2021




	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	104,956,439	2,290,488	5,806,978	136,611
New	1,417,743 in 3 days	42,784 in 3 days	72,315 in 3 days	1,252 in 3 days

Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	106,713	100,772	379	5,562	40	2,791,875
New	1,921 in 3 days	1,245 in 3 days	3 in 3 days	-	-	39,650 in 3 days


HIGHLIGHTS

- The mortality were: a 67, 73 and 99 years old male Bahraini Citizen.
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 6 February 2021 is 182,543.
- In response to recommendations made by the National Medical Taskforce to combatting the COVID-19, the following decisions were made, to be implemented from 07 February to 20 February:
 - Government entities and institutions to allow a maximum of 70% of employees to work from home.
 - Temporary closure of in-door gyms and sports halls, and swimming pools, while outdoor exercising for gyms and sports halls may continue with a maximum of 30 individuals.
 - Temporary suspension of indoor exercise classes.
 - The prohibition of all social gatherings or private events held at home, and private locations, with more than 30 individuals.
 - An overcrowded labour accommodation facility in Malkiya was found lacking basic health, safety and security measures.
 - People who have come in contact with active COVID-19 cases have been warned against visiting random testing locations.
 - Almost 100,000 people have recovered from COVID-19 in Bahrain; a significant milestone reached as medical cadre is working tirelessly to combat the latest Coronavirus spike.
 - Telemedicine has played an effective role in preventing a disruption of healthcare services during the COVID-19 pandemic in the Kingdom.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immuno assay; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines; see link below.
- WHO: Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic; see link below.
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020; see link below.
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021; see link below.
- WHO: Contact tracing in the context of COVID-19; see link below.



IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsid=649e746_4
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news/item/12-01-2021-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/2V5vdSr>
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue: <https://www.who.int/publications/item/emergency-global-supply-chain-system-covid-19-catalogue>
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immuno assays: <https://bit.ly/2RQVf>
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://www.who.int/publications/item/WHO-2019-nCoV-19202011>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: <https://www.who.int/publications/item/WHO-2019-nCoV-19202011>
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/item/9789240017467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/1066337553>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: https://www.who.int/publications/item/WHO-2019-nCoV-Policy_Brief_EUD_placebo-controlled_vaccine_trials-2020.1
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based_international_Travel_Assessment_tool-2020.1
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/12-01-2021-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health: <https://www.who.int/publications/item/9789240018440>
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: https://www.who.int/publications/item/WHO-2019-nCoV-vaccine_SAGE_recommendation-BNT162b2-2020.1
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum: <https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum>
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: https://www.who.int/publications/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: <https://www.who.int/publications/item/Background-document-on-mrna-vaccine-bnt162b2-pfizer-biontech-against-covid-19>
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum: <https://www.who.int/news/item/16-01-2021-scientists-tackle-vaccine-safety-efcacy-and-access-at-global-r-d-forum>
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines: <https://www.who.int/news/item/15-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines>
- WHO: Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic: <https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-international-health-regulations-2005-emergency-committee-regarding-the-coronavirus-disease-covid-19-pandemic>
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020: <https://www.who.int/publications/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021: <https://www.who.int/publications/item/covid-19-virtual-press-conference-transcript-1-february-2021>
- WHO: Contact tracing in the context of COVID-19: <https://www.who.int/publications/item/contact-tracing-in-the-context-of-covid-19>



IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAli5@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh